Evidence map›Paper›PMID 37055607›Full record

ArticleCellular and molecular neurobiology2023

Metastatic Melanoma: A Preclinical Model Standardization and Development of a Chitosan-Coated Nanoemulsion Containing Temozolomide to Treat Brain Metastasis.

Nicolly Espindola Gelsleichter, Priscila Oliveira de Souza, Fernanda Cardoso Teixeira, Gabriela Nogueira Debom, Gabriela Spies Lenz, Gabriela Gonçalves Roliano, Rita de Cássia Sant'ana, Fernanda Visioli, Flávia Nathiely Silveira Fachel, Luana Roberta Michels and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular and molecular neurobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Nicolly Espindola GelsleichterPrograma de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Sarmento Leite Street, 245, Centro Histórico, Porto Alegre, RS, 90050-170, Brazil.
Priscila Oliveira de SouzaPrograma de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Sarmento Leite Street, 245, Centro Histórico, Porto Alegre, RS, 90050-170, Brazil.
Fernanda Cardoso TeixeiraPrograma de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Sarmento Leite Street, 245, Centro Histórico, Porto Alegre, RS, 90050-170, Brazil.
Gabriela Nogueira DebomPrograma de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Sarmento Leite Street, 245, Centro Histórico, Porto Alegre, RS, 90050-170, Brazil.
Gabriela Spies LenzPrograma de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Sarmento Leite Street, 245, Centro Histórico, Porto Alegre, RS, 90050-170, Brazil.
Gabriela Gonçalves RolianoPrograma de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Sarmento Leite Street, 245, Centro Histórico, Porto Alegre, RS, 90050-170, Brazil.
Rita de Cássia Sant'anaPrograma de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Sarmento Leite Street, 245, Centro Histórico, Porto Alegre, RS, 90050-170, Brazil.
Fernanda VisioliFaculdade de Odontologia, Universidade Federal Do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.
Flávia Nathiely Silveira FachelPrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande Do Sul (UFRGS), Porto Alegre, RS, Brazil.
Luana Roberta MichelsPrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande Do Sul (UFRGS), Porto Alegre, RS, Brazil.
Juliana Hofstätter AzambujaPrograma de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Sarmento Leite Street, 245, Centro Histórico, Porto Alegre, RS, 90050-170, Brazil.
Helder Ferreira TeixeiraPrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande Do Sul (UFRGS), Porto Alegre, RS, Brazil.
Elizandra BraganholPrograma de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Sarmento Leite Street, 245, Centro Histórico, Porto Alegre, RS, 90050-170, Brazil. ebraganhol@ufcspa.edu.br.
Universidade Federal de Ciências da Saúde de Porto Alegre · BRUniversidade Federal do Rio Grande do Sul · BRFundação Universitária de Cardiologia · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 310846/2014-5Conselho Nacional de Desenvolvimento Científico e Tecnológico 422298/2016-6Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 001Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul 16/2551-0000265-7Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul 16/2551-0000473-0
6 · The paper itself

Abstract

Melanoma is the most aggressive type of skin cancer. Brain metastasis is the worst scenario in metastatic melanoma and the treatment options for these patients are limited. Temozolomide (TMZ) is a chemotherapy agent used to treat primary central nervous system tumors. Our objective was to develop chitosan-coated nanoemulsion containing temozolomide (CNE-TMZ) for nasal route administration to melanoma brain metastasis treatment. A preclinical model of metastatic brain melanoma was standardized, and the efficiency of the developed formulation was further determined in vitro and in vivo. The nanoemulsion was done by spontaneous emulsification method and the formulation was characterized by size, pH, polydispersity index, and zeta potential. Culture assessments to determine cell viability were done in the A375 human melanoma cell line. To determine the safety of formulation, healthy C57/BL6 mice were treated with a nanoemulsion without TMZ. The model in vivo used B16-F10 cells implanted by stereotaxic surgery in C57/BL6 mice brains. The results demonstrate that the preclinical model used showed to be useful to analyze the efficiency of new candidate drugs to treat melanoma brain metastasis. The chitosan-coated nanoemulsions with TMZ showed the expected physicochemical characteristics and demonstrated safety and efficacy, reducing around 70% the tumor size compared to control mice, and presenting a tendency in mitotic index reduction, becoming an interesting approach to treat melanoma brain metastasis.

Indexed as

Brain NeoplasmsChitosanMelanomaAnimalsCell Line, TumorDacarbazineHumansMiceTemozolomideChitosanDacarbazineTemozolomideBrain metastasisChitosanMelanomaNanoemulsionTemozolomide

Identifiers

PMID37055607
PMCPMC11410114
OpenAlexW4365449928

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.